←Back to list

Insitro

Machine learning-driven drug discovery platform founded by Stanford ML pioneer Daphne Koller
Insitro applies machine learning to generate and analyze human disease models, identifying drug targets that traditional pharma misses. Founded by Daphne Koller (Coursera co-founder, ex-Stanford CS / Calico chief computing officer). Pipeline partnerships with BMS and Gilead worth $2B+ in milestones. CPP Investment Board-led Series C valued the company at $2.4B in 2021.
Biotech 📍 South San Francisco, CA Founded 2018
Current Valuation
$2.4B
as of 2021-Q1
UNICORN

QL Price

$1.7B
-28% vs last round
QuantLogix's current estimate for Insitro, published 2026-10-07 — below the last disclosed round of $2.4B (2021-Q1).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round $2.4B 2021-Q1 weight 0.02
Secondary market print $1.7B 2026-06-27 weight 0.54
How this price has held up
No round has priced for Insitro since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-10-07 and will be graded against the next priced round. See the full accuracy record →
How to actually get exposure to Insitro →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Insitro, 2026-10-07 (19672f335f8a5aee). The id pins this exact claim, so a citation stays checkable after the price moves. Model estimate for research — not a quote, target price, or investment advice.

IPO Outlookprivate

Is Insitro going public?
No. Insitro has no imminent IPO plans on record. It is still private.
What is Insitro's valuation in 2026?
Insitro is valued at $2.4B as of 2021-Q1, set by its Series C ($400M, Mar 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Insitro filed an S-1?
No public S-1 is on file for Insitro.
Who are Insitro's investors?
Insitro's investors include Canada Pension Plan Investment Board, Andreessen Horowitz, ARCH Venture Partners, Foresite Capital, GV, T. Rowe Price and 2 more.
How much has Insitro raised?
Insitro has raised $743M in total, most recently a Series C of $400M in Mar 2021.
Is Insitro publicly traded — can you buy Insitro stock?
No. Insitro is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Insitro on its Pre-IPO Access Desk.
How to actually get exposure to Insitro →
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.

Company Profile

CEO
Daphne Koller
Founded
2018
HQ
South San Francisco, CA
Employees
~250
Total Raised
$743M
Growth
Pre-revenue (collaboration milestones)
Last Round
Series C — $400M (Mar 2021) · Lead: Canada Pension Plan Investment Board
IPO Status
no imminent plans

Fundraising Status

Series C · $400M · 5y 7mo ago
no imminent plansTotal raised $743M

Secondary Market

Implied price / share
$12.94
Last round price / share
$18.29
vs last round
-29.3%
Last round price vs secondary price
Last round vs current secondary price per share$18.29Last round$12.94Current
Secondary price return by period
Secondary market period returns3-month0.0%6-month+0.3%1-year+1.7%All-time-56.9%
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →

Latest Funding Round

RoundAmountDateLead InvestorPost-Money
Series C$400MMar 2021Canada Pension Plan Investment Board—

Vertical Intelligence — Biotech / Gene Therapy

No name-verified sponsor record on ClinicalTrials.gov for Insitro — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-10-04. Re-checked weekly.

Talent Signal

Hiring trend
▶ Hiring steady
+7% vs 2026-08
Open roles
15
via ashby
Product-build share
47%
engineering, research, product, design
Trajectory
steady
product-led hiring — 47% of open roles build product; the rest are go-to-market and G&A.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by month14Aug '2615Sep '26
Open roles by function
Open roles by functionOther5Research4Engineering2Legal & Policy2Data & ML1Ops & People1
■ product-building   ■ go-to-market / G&A
Senior Machine Learning Scientist, Imaging(Senior) ML ScientistSenior Manager, Imaging Machine LearningSenior Automation EngineerStaff Software Engineer, ImagingSenior Scientist, Cardiac Modeling
Counted from Insitro's live job board as of 2026-09-15; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.

Founders & Key People

Daphne Koller

Investors

Canada Pension Plan Investment Board · Andreessen Horowitz · ARCH Venture Partners · Foresite Capital · GV · T. Rowe Price · Bezos Expeditions · Casdin Capital

Products

  • Insitro Human (in vitro disease models)
  • Insitro ML platform
  • Therapeutic pipeline (NAFLD, ALS, neuro)

Competitors

Recursion Pharmaceuticals · Isomorphic Labs · Atomic AI · Xaira Therapeutics · Generate Biomedicines
BiotechAI Drug DiscoveryMachine Learning
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q1. Refreshed quarterly.